Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$30.03 USD

30.03
3,104,970

-0.51 (-1.67%)

Updated Apr 25, 2024 12:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 16% (211 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche's (RHHBY) Application for PNH Drug Accepted by FDA

by Zacks Equity Research

Roche (RHHBY) biologics license application seeking approval for crovalimab for paroxysmal nocturnal hemoglobinuria gets FDA acceptance.

AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why

by Zacks Equity Research

AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for neurodegenerative diseases.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's New '23 View After Kenvue Separation, Regulatory Updates

by Kinjel Shah

J&J (JNJ) updates its financial guidance for 2023 after the final separation of Kenvue. Pfizer, BioNTech, Merck and AbbVie announce regulatory developments.

Roche's (RHHBY) Late-Stage Lung Cancer Study Meets Primary Goal

by Zacks Equity Research

Roche's (RHHBY) late-stage ALK-positive non-small cell lung cancer study evaluating Alecensa meets the primary endpoint of disease-free survival.

Regeneron (REGN) Gains 13% in 1 Month on FDA Nod For Eylea HD

by Zacks Equity Research

Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.

Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns

by Zacks Equity Research

Following the label expansion, Roche's (RHHBY) Evrysdi is now approved to treat people of all ages with SMA in the European Union.

The Zacks Analyst Blog Highlights Alphabet, Roche Holding, Honeywell International, IBM and The Goldman Sachs

by Zacks Equity Research

Alphabet, Roche Holding, Honeywell International, IBM and The Goldman Sachs are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Alphabet, Roche & Honeywell International

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Roche Holding AG (RHHBY) and Honeywell International Inc. (HON).

Kinjel Shah headshot

Pharma Stock Roundup: PFE Gets Nod for RSV Vaccine, J&J Finalizes Kenvue Separation

by Kinjel Shah

FDA and EU approve Pfizer's (PFE) RSV vaccine, Abrysvo for maternal immunization. J&J (JNJ) finalizes separation of its Consumer Health company, Kenvue.

Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak

by Zacks Equity Research

Shares of several companies developing anti-TIGIT therapies rise after Roche (RHHBY) accidentally leaks encouraging late-stage study data.

Roche (RHHBY) Up on Upbeat Data From Combo Drug Cancer Study

by Zacks Equity Research

Roche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging second interim analysis data from its combination drug study to treat cancer.

Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint

by Zacks Equity Research

Exelixis (EXEL) and partner Ipsen's phase III CONTACT-02 study meets one of the two primary endpoints in prostate cancer patients.

Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal

by Zacks Equity Research

Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.

Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study

by Zacks Equity Research

Sonnet (SONN) receives FDA clearance to begin clinical development for its combination therapy of SON-1010 and Roche's atezolizumab, for the potential treatment of platinum-resistant ovarian cancer.

Galecto (GLTO) Down 71% as Lung Disease Candidate Fails

by Zacks Equity Research

Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.

Novartis (NVS) Key Drugs and Pipeline Progress Fuel Growth

by Zacks Equity Research

Novartis (NVS) put up a strong performance year to date based on the solid performance of key drugs and encouraging pipeline progress.

Abbott (ABT) Gains in Core Diagnostics With FDA Nod for Alinity H

by Zacks Equity Research

Abbott's (ABT) Alinity h-series not only delivers technological innovation but also addresses the realistic challenges faced by modern healthcare systems.

Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised

by Zacks Equity Research

Halozyme (HALO) shares rise 4% in the after-market trading hours on better-than-expected second-quarter 2023 results, boosted by collaboration and royalty revenues. Management raises its 2023 guidance.

Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.

Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Prothena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-line guidance.

Regeneron (REGN) Q2 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again.

Sarepta (SRPT) Q2 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Sarepta's (SRPT) second-quarter 2023 earnings beat estimates. Though total revenues register strong year-over-year growth during the quarter, the same misses the mark.

Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Blueprint (BPMC) reports better-than-expected second-quarter 2023 results, driven by increased Ayvakit sales, following FDA approval in a new indication.

Roche (RHHBY) 1H Revenues, Earnings Down on Lower COVID-19 Test Sales

by Zacks Equity Research

Roche's (RHHBY) performance in the first half of 2023 was ordinary as COVID-19-test sales continue to decline and dent the top line.

Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts

by Zacks Equity Research

Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.